



ABIVAX

HALF-YEAR REPORT ON THE LIQUIDITY CONTRACT AT 30 JUNE 2016

Paris, July 6th, 2016

Regarding the liquidity contract assigned by ABIVAX (ISIN code: **FR0012333284**, ticker: **ABVX**) to TSAF – Tradition Securities And Futures – on June 26th, 2015, the liquidity account held the following amounts on June 30, 2016:

- 52 100 shares
- €129,752.62

As a reminder, the liquidity account held the following amounts at December 31, 2015:

- 43,446 shares
- €195,505.60

ABIVAX is an innovative biotechnology company in the discovery and development of anti-viral therapeutics and immunotherapeutics to treat some of the world's most life-threatening infectious diseases, including HIV/AIDS and chronic Hepatitis B. ABIVAX has 2 compounds in clinical stage research: ABX464 a novel first-in-class resistance-proof oral small molecule HIV/AIDS therapy; and, ABX203, an immunotherapy recently approved in Cuba and in late-stage clinical development in other countries that could cure chronic Hepatitis B. ABIVAX also is advancing additional anti-viral compounds and immunotherapeutics that may enter the clinical stage in the coming 18 months. A recently updated corporate presentation, which includes a timeline for the company's anticipated news flow, is available at www.abivax.com. Follow us on Twitter @ABIVAX

Contacts :

Investor Relations

Raquel Lizarraga
raquel.lizarraga@abivax.com
+33 1 53 83 09 63

Press Relations

ALIZE RP
Caroline Carmagnol and Florence Portejoie
abivax@alizerp.com
+33 6 64 18 99 59 / + 33 1 44 54 36 64